Could a common arthritis pill tame Chemo's worst side effect?

NCT ID NCT00159484

Completed Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding the arthritis drug Celebrex to an experimental chemo drug called EPO906 could reduce severe diarrhea in people with advanced colorectal cancer. The trial enrolled 75 patients who had already tried other treatments. The first phase found the safest dose of EPO906 when combined with Celebrex, and the second phase looked at how well the tumors responded.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Celecoxib (Celebrex) and epothilone B (EPO906)
What this could lead to: If successful, this combination could offer a new treatment option for advanced colorectal cancer with fewer severe side effects.
What could go wrong: This is an early-phase trial with a small number of participants. The experimental drug EPO906 is not FDA-approved, and the combination may still cause serious side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER COLORECTAL CANCER

Contacts and locations

Locations

U.S.C./Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.